Latest News on SYRE

Financial News Based On Company


Advertisement
Advertisement

SYRE: IBD Phase II results next year will determine which long-acting combinations advance to Phase III

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4664577:0-syre-ibd-phase-ii-results-next-year-will-determine-which-long-acting-combinations-advance-to-phase-iii/
Spyre Therapeutics (SYRE) is developing optimized IBD and HS antibodies, including co-formulated combinations for strong efficacy and infrequent dosing. The company expects to release IBD Phase II data in Q3 of next year, which will inform decisions on which combinations will progress to Phase III trials. This strategy aims to streamline therapeutic development based on clinical results.

Should Wider Losses Require Action From Spyre Therapeutics (SYRE) Investors?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/should-wider-losses-require-action-from-spyre-therapeutics-s
Spyre Therapeutics reported widening net losses for Q3 2026 and the nine-month period, reflecting increased spending as a clinical-stage business. While the larger losses highlight its pure development story, the company maintains a strong cash buffer until H2 2029, with key Phase 2 trial data expected in Q4 2026 for its inflammatory bowel disease and autoimmune pipeline. Investors should monitor sustained cash burn and trial outcomes, as the market currently suggests a potential 19% upside to its fair value.

Following Earnings Losses, Is Spyre Therapeutics (SYRE) Still Worth Its 11x P/B?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/following-earnings-losses-is-spyre-therapeutics-syre-still-w
Spyre Therapeutics (SYRE) recently reported a significant net loss of US$96.12 million for the third quarter, sharply widening per-share losses and causing choppy share price reactions despite strong longer-term momentum. The stock currently trades at a price-to-book (P/B) ratio of 11x, considerably higher than its peer average of 4.3x, raising questions about whether this valuation is justified given the company's losses and lack of revenue. The high P/B ratio suggests the market is valuing its future pipeline potential heavily, but this optimism is balanced against the risks of clinical trial setbacks or funding strains.

Spyre managers will meet investors one-on-one in London and Miami.

https://www.stocktitan.net/news/SYRE/spyre-therapeutics-to-participate-in-upcoming-investor-jmykobmz62hc.html
Spyre Therapeutics (NASDAQ: SYRE) announced its participation in four investor conferences in November and December 2026, taking place in London and Miami. Management will attend the UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, 9th Annual Evercore Healthcare Conference, and Citi’s 2026 Global Healthcare Conference. The company will also host one-on-one investor meetings, with live audio webcasts and replays available on its investor events website.

Spyre Therapeutics stock hits 52-week high at 110.28 USD By Investing.com

https://ca.investing.com/news/stock-market-news/spyre-therapeutics-stock-hits-52week-high-at-11028-usd-93CH-4944156
Spyre Therapeutics (SYRE) stock has reached a new 52-week high of 110.28 USD, reflecting a 361% one-year return and a 217% year-to-date surge, pushing its market capitalization to 10.44 billion USD. Despite this, InvestingPro data suggests the stock is currently overvalued. The company has recently received positive analyst coverage from UBS, JPMorgan, Baird, Guggenheim, and Stifel, highlighting its strong pipeline in inflammatory bowel disease and promising Phase II results in rheumatoid arthritis.
Advertisement

How Investors May Respond To Spyre Therapeutics Stock After Phase 2 Data And Wider Losses

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/how-investors-may-respond-to-spyre-therapeutics-stock-after
Spyre Therapeutics (NasdaqGS:SYRE) reported a Q3 2026 net loss of US$96.12 million, or US$0.94 per share, despite positive Phase 2 data for SPY003 in inflammatory bowel disease. The company is increasing its investment in late-stage trials, particularly for hidradenitis suppurativa, indicating a strategy of higher spending to advance its multi-asset autoimmune pipeline. While community fair value estimates show optimism, the widening losses and increased trial spend highlight execution risks and a reliance on successful clinical outcomes to justify its valuation.

Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 16c

https://www.streetinsider.com/Earnings/Spyre+Therapeutics%2C+Inc.+%28SYRE%29+Misses+Q3+EPS+by+16c/27283334.html
Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported a Q3 EPS of ($0.94), which missed the analyst estimate of ($0.78) by $0.16. The article provides the financial details and links to further earnings-related data for the company.

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.stocktitan.net/news/SYRE/spyre-therapeutics-reports-third-quarter-2026-financial-results-and-qrg3j79acskq.html
Spyre Therapeutics (SYRE) reported a widened net loss of $96.1 million for Q3 2026, up from $11.2 million a year prior, but also announced positive Phase 2 SKYLINE monotherapy results for ulcerative colitis. The company discontinued SPY072 development in rheumatic diseases due to missed primary endpoints and insufficient benefit but is advancing SPY072 into pivotal studies for hidradenitis suppurativa in 2027. Spyre secured over $400 million in October financing, extending its cash runway into the second half of 2029.

Spyre Therapeutics, Inc Estimates – XETR:3920

https://www.tradingview.com/symbols/XETR-3920/financials-estimates/
This article provides financial estimates for Spyre Therapeutics, Inc (XETR:3920), offering an overview of reported financial data and analyst estimates across various financial statements and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time. The information is presented by TradingView, sourced from ICE Data Services and FactSet.

Spyre Therapeutics, Inc. Estimates – NASDAQ:SYRE

https://www.tradingview.com/symbols/NASDAQ-SYRE/financials-estimates/
This article provides an overview of Spyre Therapeutics, Inc. (NASDAQ:SYRE) financial estimates available on TradingView. It highlights where users can explore reported financial data, analyst estimates across various statements, and compare actual results with average, high, and low estimates. The content emphasizes that the information is not investment advice and encourages users to conduct their own research.
Advertisement

Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $119

https://www.moomoo.com/news/post/1001870196/citi-maintains-spyre-therapeutics-syreus-with-buy-rating-maintains-target
Citi has reiterated its Buy rating for Spyre Therapeutics (SYRE.US) and maintained its target price at $119. This indicates a continued positive outlook from the investment bank regarding the company's stock performance.

SYRE Stock Whipsaws As Bullish Targets Clash With Dilution Hit

https://stockstotrade.com/news/spyre-therapeutics-inc-syre-news-2026_10_20/
Spyre Therapeutics Inc. (SYRE) stock experienced significant volatility, whipsawing due to conflicting market signals. While major banks like Jones, UBS, and JPMorgan issued bullish price targets based on clinical development optimism and a projected multi-billion-dollar inflammatory bowel disease market, a substantial $350 million equity offering caused a significant dip due to dilution concerns. Traders are now watching key technical levels and upcoming clinical data presentations for further direction.

Las ETF que invierten en acciones de Spyre Therapeutics, Inc

https://es.tradingview.com/symbols/XETR-3920/etfs/
This article lists Exchange Traded Funds (ETFs) that hold shares of Spyre Therapeutics, Inc. It provides a detailed table of these funds, including their market value, percentage weight of Spyre Therapeutics, Inc. stock, issuer, management style, expense ratio, assets under management (AUM), price, and various performance metrics. The information aims to assist investors interested in Spyre Therapeutics, Inc. by identifying diversified investment vehicles.

BTIG reiterates Buy rating on Spyre Therapeutics, $121 price target

https://www.tradingview.com/news/tradingview:501f644d3647e:0-btig-reiterates-buy-rating-on-spyre-therapeutics-121-price-target/
BTIG has reiterated its Buy rating on Spyre Therapeutics (SYRE) with a price target of $121.00, representing a potential upside of 51.4% from its October 16 close. This positive outlook is supported by strong Phase 2b trial data for tulisokibart, demonstrating competitive efficacy and a good safety profile for inflammatory bowel disease, as well as the company's robust pipeline of long-acting antibodies.

Spyre Therapeutics (SYRE) to Present New IBD Antibody Data at UEGW 2026

https://www.gurufocus.com/news/9129048/spyre-therapeutics-syre-to-present-new-ibd-antibody-data-at-uegw-2026
Spyre Therapeutics (SYRE) announced it will present new clinical and preclinical data on its IBD antibody therapies at UEGW 2026, marking the first scientific disclosure from its SKYLINE study. Despite a high price-to-sales ratio and unprofitability, the market anticipates significant future growth. The company's GF Score is 32/100, reflecting strong financial health but weak valuation and profitability, with mixed guru activity and significant insider selling.
Advertisement

Mouse studies found combinations of experimental bowel treatments worked better

https://www.stocktitan.net/news/SYRE/spyre-therapeutics-announces-clinical-and-preclinical-data-3iguth2kgsdv.html
Spyre Therapeutics (NASDAQ: SYRE) announced presentations of clinical and preclinical data for its inflammatory bowel disease antibodies at United European Gastroenterology Week 2026. Preclinical findings in humanized mice with experimentally induced colitis showed improved efficacy with antibody combinations. The company highlighted that its three IBD antibodies—SPY001, SPY002, and SPY003—are being tested individually and in pairwise combinations in the SKYLINE study, with a focus on achieving deeper and more durable responses for IBD patients.

Fairmount Funds Management LLC Acquires 10,185,961 Shares of Spyre Therapeutics Inc (SYRE)

https://www.gurufocus.com/news/9124869/fairmount-funds-management-llc-acquires-10185961-shares-of-spyre-therapeutics-inc-syre
Fairmount Funds Management LLC has acquired 10,185,961 shares of Spyre Therapeutics Inc (SYRE) for $80.85 per share, representing 35.25% of Fairmount's portfolio and 9.99% of Spyre's total shares. This significant investment in the clinical-stage biotechnology company highlights Fairmount's high conviction in Spyre's pipeline, despite the inherent risks and the company's current lack of product revenue. The transaction underscores a strategic interest in innovative biopharmaceutical firms, particularly those focused on inflammatory bowel disease and rheumatic diseases.

UBS Initiates Spyre Therapeutics at Buy With $120 Price Target

https://finance.yahoo.com/markets/stocks/articles/ubs-initiates-spyre-therapeutics-buy-114409002.html
UBS has initiated coverage of Spyre Therapeutics (SYRE) with a "Buy" rating and a $120 price target. This aligns closely with the average analyst rating of "buy" and a mean price target of $121.57 for the company. Access to the full article content requires a premium subscription.

UBS Initiates Spyre Therapeutics at Buy With $120 Price Target

https://www.moomoo.com/news/post/1000932811/ubs-initiates-spyre-therapeutics-at-buy-with-120-price-target
UBS has initiated coverage of Spyre Therapeutics with a Buy rating and a price target of $120. This rating suggests a positive outlook for the company's stock by the investment bank.

SYRE Initiates Coverage by UBS -- Price Target Set at $120.00

https://www.gurufocus.com/news/9119268/syre-initiates-coverage-by-ubs-price-target-set-at-12000
UBS has initiated coverage on Spyre Therapeutics (SYRE) with a 'Buy' rating and a price target of $120.00, despite the company's GF Score™ of 32/100, which indicates below-average performance in key financial metrics. The biotechnology company, with a market capitalization of approximately $7.94 billion, shows a high price-to-sales ratio of 49.12 and has seen significant insider selling, suggesting caution for investors despite the positive analyst outlook.
Advertisement

UBS initiates Spyre stock with buy rating on IBD therapy potential

https://ng.investing.com/news/stock-market-news/ubs-initiates-spyre-stock-with-buy-rating-on-ibd-therapy-potential-93CH-2730837
UBS has initiated coverage on Spyre Therapeutics Inc. (NASDAQ:SYRE) with a Buy rating and a $120 price target, anticipating significant growth from its inflammatory bowel disease (IBD) therapy pipeline. The firm believes Spyre is well-positioned to capitalize on the IBD market, projected to reach $40 billion to $50 billion by 2035, with an expected Phase 2 readout in 2027 serving as a key catalyst. Despite potential near-term volatility due to readouts in non-IBD indications, UBS forecasts substantial unadjusted and adjusted sales for Spyre's IBD portfolio by 2035, exceeding consensus estimates.

UBS initiates Spyre stock with buy rating on IBD therapy potential

https://ca.investing.com/news/stock-market-news/ubs-initiates-spyre-stock-with-buy-rating-on-ibd-therapy-potential-93CH-4875189
UBS has initiated coverage on Spyre Therapeutics Inc. (NASDAQ:SYRE) with a Buy rating and a $120 price target, citing the company's strong position in the inflammatory bowel disease (IBD) combination therapy market, which is projected to reach $40-50 billion by 2035. The firm expects Spyre's Phase 2 ulcerative colitis readout in 2027 to be a key catalyst and forecasts significant sales for its IBD portfolio, exceeding consensus estimates. Despite anticipated near-term volatility due to TL1A class readouts, UBS remains bullish on Spyre's long-term potential in this therapeutic area.

Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/SYRE/
This Yahoo Finance page provides a comprehensive overview of Spyre Therapeutics, Inc. (SYRE), including its current stock price, recent news, historical data, and financial analysis. The company is a clinical-stage biotechnology firm focused on developing treatments for inflammatory bowel disease and rheumatic diseases, with several drug candidates in various phases of clinical trials. Recent news highlights include a $350.0 million public offering of common stock and positive results from its SPY003 anti-IL-23 antibody study for ulcerative colitis.

A 60-day lock-up at Spyre Therapeutics (SYRE) bars Fairmount sales without underwriters’ consent.

https://www.stocktitan.net/sec-filings/SYRE/schedule-13d-a-spyre-therapeutics-inc-amended-major-shareholder-repor-fee345a7b505.html
Fairmount Funds Management LLC and affiliated reporting persons have entered into a 60-day lock-up agreement for their Spyre Therapeutics (SYRE) securities. This agreement prevents them from selling shares without underwriters' consent following the company's recent public offering, which closed on October 7, 2026. The reporting persons did not participate in the offering and their share counts have remained consistent since June 23, 2026.

Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering

https://finance.yahoo.com/healthcare/articles/spyre-therapeutics-syre-completed-350-171555577.html
Spyre Therapeutics (SYRE) has completed a $350 million public stock offering to fund its drug pipeline, particularly advancing clinical programs in gastroenterology, rheumatology, and dermatology. This equity raise aims to provide a cash runway until 2029 for multiple Phase 2 and Phase 3 ready programs, despite a roughly 5% share dilution. The company's focus remains on expensive late-stage trials for inflammatory bowel disease and rheumatic conditions, with investors keenly awaiting data from its SKYLINE and SKYWAY trials.
Advertisement

Spyre Therapeutics Launches $350 Million Stock Offering Underwritten by Jefferies, TD, Leerink, Stifel

https://www.tradingview.com/news/tradingview:1af8ed16c210a:0-spyre-therapeutics-launches-350-million-stock-offering-underwritten-by-jefferies-td-leerink-stifel/
Spyre Therapeutics is launching a public offering of 4,117,648 shares of common stock at $85.00 per share, aiming to raise approximately $350 million. The offering is underwritten by Jefferies, TD Securities, Leerink Partners, and Stifel, with an expected closing date of October 7, 2026. Proceeds will fund advancements in gastroenterology, rheumatology, and dermatology programs, prepare for Phase 3, progress SPY072 into late-stage development, support infrastructure, and pursue potential in-licensing or acquisitions.

Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market

https://finance.yahoo.com/healthcare/articles/spyre-therapeutics-sinks-14-upsized-174005484.html
Spyre Therapeutics (SYRE) saw its stock drop 14% after announcing an upsized $350 million stock offering priced at $85 per share, approximately 8% below Monday's closing price. This offering, which adds roughly 5% more stock, will boost the company's cash reserves to about $1.1 billion for funding Phase 3 readiness and late-stage trials of SPY072. The dilution and discounted pricing led to the stock trading below the offering price on day one, reflecting a common scenario in biotech financing where companies raise capital when stock is strong to fund pipeline development.

Spyre Shares Fall After Pricing $350 Million Stock Offering

https://www.marketscreener.com/news/spyre-shares-fall-after-pricing-350-million-stock-offering-ce785dd9dd80f025
Spyre Therapeutics' shares dropped following the pricing of a $350 million stock offering. The company is a clinical-stage biotechnology firm focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases. Recent news highlighted positive Phase 2 data for its SPY003 drug and insider share sales.

Spyre Therapeutics Prices $350 Million Public Offering of Common Stock

https://www.quiverquant.com/news/Spyre+Therapeutics+Prices+%24350+Million+Public+Offering+of+Common+Stock
Spyre Therapeutics has priced an underwritten public offering of 4,117,648 shares of common stock at $85.00 per share, aiming to raise approximately $350 million. The proceeds will fund the advancement of their programs in Gastroenterology, Rheumatology, and Dermatology, including late-stage development for hidradenitis suppurativa. The offering is expected to close around October 7, 2026, with Jefferies, TD Cowen, Leerink Partners, and Stifel managing the process.

Spyre Therapeutics stock falls on public offering launch

https://www.investing.com/news/stock-market-news/spyre-therapeutics-stock-falls-on-public-offering-launch-4932850
Spyre Therapeutics (NASDAQ:SYRE) shares dropped 2.9% after announcing a public offering of its common stock. The company plans to use the proceeds to advance its clinical programs in Gastroenterology, Rheumatology, and Dermatology, including funding for preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, and to advance SPY072 into late-stage development. The offering is subject to market conditions, and its completion, size, or terms are not assured.
Advertisement

Spyre Therapeutics prices $350M public offering at $85 per share

https://www.tradingview.com/news/seekingalpha:aa02c10cc094b:0-spyre-therapeutics-prices-350m-public-offering-at-85-per-share/
Spyre Therapeutics announced the pricing of an underwritten public offering of 4.12 million shares of common stock at $85.00 per share, aiming to raise approximately $350 million. The company plans to use the proceeds to advance its clinical pipeline in Gastroenterology, Rheumatology, and Dermatology, including funding preclinical work, clinical trials, and manufacturing. A portion of the funds will also support the late-stage development of SPY072 for hidradenitis suppurativa, with remaining proceeds allocated to research and development and general corporate purposes.

Spyre Therapeutics prices $350M stock offering at $85/share

https://www.investing.com/news/company-news/spyre-therapeutics-prices-350m-stock-offering-at-85share-93CH-4933138
Spyre Therapeutics Inc. has priced an underwritten public offering of 4,117,648 shares of common stock at $85.00 per share, expecting to raise approximately $350.0 million in gross proceeds. The company plans to use these proceeds to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including funding preclinical studies, clinical trials, and manufacturing. This also includes moving SPY072 into late-stage development for hidradenitis suppurativa, with remaining funds allocated to general research, development, and corporate purposes.

Spyre Therapeutics launches public stock offering

https://www.investing.com/news/company-news/spyre-therapeutics-launches-public-stock-offering-93CH-4932800
Spyre Therapeutics Inc. has announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters an option to purchase additional shares. The biotechnology company intends to use the net proceeds to advance its gastroenterology, rheumatology, and dermatology programs, including funding for preclinical studies, clinical trials, and late-stage development of SPY072. The offering is contingent on market conditions, and its completion, size, and terms are not guaranteed.

Spyre Therapeutics launches underwritten public offering of common stock

https://scanx.trade/stock-market-news/ipo/spyre-therapeutics-launches-underwritten-public-offering-common-stock/52776459
Spyre Therapeutics has initiated an underwritten public offering of its common stock to finance its immunology pipeline, focusing significantly on advancing SPY072 into late-stage development for hidradenitis suppurativa. The net proceeds are intended for preclinical studies, clinical trials, and manufacturing, with Jefferies, TD Cowen, Leerink Partners, and Stifel acting as joint book-running managers. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares, providing flexibility for further capital if demand is high.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

https://www.stocktitan.net/news/SYRE/spyre-therapeutics-announces-proposed-public-offering-of-its-common-z5ghi26ykv6y.html
Spyre Therapeutics has announced a proposed underwritten public offering of common stock to secure funding for its ongoing development programs. The proceeds will primarily support advancing its Gastroenterology, Rheumatology, and Dermatology programs through clinical stages, including Phase 3 readiness, and initiating late-stage development for SPY072 in hidradenitis suppurativa. The offering's completion is contingent on market and other conditions.
Advertisement

Spyre Therapeutics Commences Public Offering of Common Stock

https://finance.yahoo.com/healthcare/articles/spyre-therapeutics-commences-public-offering-201711030.html
Spyre Therapeutics (SYRE) has initiated an underwritten public offering of its common stock. The article, however, is a premium piece and requires a subscription to view the full details.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

https://finance.yahoo.com/healthcare/articles/spyre-therapeutics-announces-proposed-public-200100494.html
Spyre Therapeutics, Inc. has announced the commencement of an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The company plans to use the net proceeds to advance its Gastroenterology, Rheumatology, and Dermatology programs, including funding preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, as well as a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Jefferies, TD Cowen, Leerink Partners, and Stifel are acting as joint book-running managers.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

https://www.pmg-ky3.com/ap/ap_news/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock/article_a9cbc507-7563-5cc7-9de1-b734121a2221.html
Spyre Therapeutics, Inc. (Nasdaq: SYRE) announced an underwritten public offering of its common stock, with underwriters having a 30-day option to purchase an additional 15%. The company plans to use the proceeds to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including funding preclinical studies, clinical trials, manufacturing, and late-stage development for SPY072 for hidradenitis suppurativa, as well as general corporate purposes. The offering is managed by Jefferies, TD Cowen, Leerink Partners, Stifel, and LifeSci Capital, and is subject to market and other conditions.

Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115

https://www.moomoo.com/news/post/1000578218/wells-fargo-maintains-spyre-therapeutics-syreus-with-buy-rating-maintains
Wells Fargo has reiterated its Buy rating for Spyre Therapeutics (SYRE.US), maintaining its price target at $115. This suggests continued confidence from Wells Fargo in the company's financial prospects and stock performance.

Spyre Therapeutics’ chief legal officer sells $2.63m in shares

https://www.investing.com/news/insider-trading-news/spyre-therapeutics-chief-legal-officer-sells-263m-in-shares-93CH-4930743
Spyre Therapeutics' chief legal officer, Heidy King-Jones, sold shares worth over $2.63 million on October 1, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan. Despite the stock's significant surge over the past year, InvestingPro analysis suggests it may be overvalued.
Advertisement

CEO Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE)

https://www.gurufocus.com/news/9108454/ceo-cameron-turtle-sells-15000-shares-of-spyre-therapeutics-inc-syre
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on October 1, 2026, at $92.01 per share. This transaction is part of a larger trend of insider selling at SYRE, with 30 insider sells and 0 buys over the past year. Investors are advised to consider this insider activity alongside the company's clinical pipeline progress and financial position.

Spyre Therapeutics CEO Cameron Turtle sells $1.38m in SYRE stock

https://www.investing.com/news/insider-trading-news/spyre-therapeutics-ceo-cameron-turtle-sells-138m-in-syre-stock-93CH-4930685
Spyre Therapeutics CEO Cameron Turtle sold 14,000 shares of SYRE stock for approximately $1.38 million on October 1, 2026, under a Rule 10b5-1 trading plan. This sale follows a significant 487% surge in the stock over the past year, though InvestingPro analysis suggests it's currently overvalued. The company faces profitability challenges despite recent mixed clinical trial results and varying analyst ratings.

Spyre Therapeutics grants inducement awards to two employees

https://scanx.trade/stock-market-news/companies/spyre-therapeutics-grants-inducement-awards-two-employees/52517312
Spyre Therapeutics has granted equity inducement awards to two new non-executive employees, including 21,424 stock options and 6,604 restricted stock units (RSUs). These awards, approved under the 2018 Equity Inducement Plan and compliant with Nasdaq rules, are intended to facilitate the employees' acceptance of employment. The grants feature a 10-year term for stock options with an exercise price of $89.93, vesting over four years, while RSUs vest on specific quarterly calendar anniversaries.

CEO Cameron Turtle sells 15,000 shares of Spyre Therapeutics (SYRE) under a trading plan.

https://www.stocktitan.net/sec-filings/SYRE/form-4-spyre-therapeutics-inc-insider-trading-activity-ffd454ff4d2b.html
Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on October 1, 2026, through six transactions under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices ranging from $89.14 to $93.37, and one transaction at $93.91. Following these sales, Turtle's direct holdings in common stock are 537,540 shares.

After exercising $14.50 options, Spyre Therapeutics (SYRE) legal chief sells 28,933 shares.

https://www.stocktitan.net/sec-filings/SYRE/form-4-spyre-therapeutics-inc-insider-trading-activity-c82e11cf770f.html
Heidy King-Jones, Chief Legal Officer and Corporate Secretary of Spyre Therapeutics (SYRE), exercised options for 28,933 common shares at $14.50 per share on October 1, 2026. She subsequently sold these shares in five separate transactions under a Rule 10b5-1 trading plan, with weighted-average sale prices ranging from $89.24 to $93.46 per share. Following these transactions, her reported post-exercise stock-option position was 482,478 underlying shares.
Advertisement

Spyre Therapeutics Officer Heidy King-Jones Files Form 144 to Sell 29,335 Shares Under 10b5-1 Plan

https://kalkinemedia.com/us/news/announcements/spyre-therapeutics-officer-heidy-king-jones-files-form-144-to-sell-29335-shares-under-10b5-1-plan
Heidy King-Jones, an officer at Spyre Therapeutics (NASDAQ:SYRE), has filed a Form 144 to sell 29,335 shares of common stock, valued at over $2.6 million, under a pre-established Rule 10b5-1 trading plan. These shares will be acquired through stock option exercises. King-Jones has also made previous sales under the same plan in September 2026.

J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $110

https://www.moomoo.com/news/post/1000503624/jp-morgan-initiates-spyre-therapeutics-syreus-with-buy-rating-announces
J.P. Morgan has initiated coverage on Spyre Therapeutics (SYRE.US) with a "Buy" rating. The investment bank has set a target price of $110 for the company's stock. This new rating and price target indicate a positive outlook from J.P. Morgan regarding Spyre Therapeutics' future performance.

45,000 shares are proposed for sale at Spyre Therapeutics (SYRE), following two earlier sales.

https://www.stocktitan.net/sec-filings/SYRE/144-spyre-therapeutics-inc-sec-filing-622947a59d61.html
Cameron Turtle has filed a Form 144 notice to sell 45,000 common shares of Spyre Therapeutics (SYRE) with an aggregate market value of $4.01 million. These shares were obtained from previously exercised stock options dated June 15, 2023, and the approximate sale date is October 1, 2026. The filing also reports two prior 10b5-1 sales: 15,000 shares on August 3, 2026, for $1.43 million, and another 15,000 shares on September 1, 2026, for $1.31 million.

After a $2.44M September sale, an officer proposes selling more Spyre Therapeutics (SYRE) shares.

https://www.stocktitan.net/sec-filings/SYRE/144-spyre-therapeutics-inc-sec-filing-2dc5c43e7589.html
Heidy King-Jones, an officer at Spyre Therapeutics (SYRE), plans to sell 29,335 common shares worth approximately $2.61 million on October 1, 2026. This proposed sale follows two previous 10b5-1 sales by King-Jones in September 2026, totaling over $2.4 million. The shares were and will be acquired through stock-option exercises.

Spyre stock draws new Overweight at J.P. Morgan (SYRE:NASDAQ)

https://seekingalpha.com/news/4649325-spyre-stock-draws-new-overweight-jp-morgan
J.P. Morgan initiated coverage on Spyre Therapeutics (SYRE) with an Overweight rating and a $110 price target for year-end 2027. Analyst Hardik Parikh highlighted the company's strong potential in treating inflammatory bowel disease (IBD) as the primary driver for the positive outlook. This news led to a rise in Spyre Therapeutics' stock price on Thursday.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement